Cybin Inc. Secures Patent for Psychedelic-Based Depression Treatment

LOS ANGELES- Cybin Inc., a biopharmaceutical company dedicated to improving mental healthcare through psychedelic-based therapies, has announced the granting of a new U.S. patent for its CYB003 program, aimed at treating Major Depressive Disorder (MDD). The patent, U.S. 11,958,807, is expected to ensure exclusivity for the company’s innovative treatments until at least 2041.

The patent specifically covers pharmaceutical compositions related to Cybin’s proprietary deuterated psilocybin analog program, CYB003. This development represents a key component of the company’s strategy to protect and advance its intellectual property in the burgeoning field of psychedelic medicine.

Doug Drysdale, CEO of Cybin, stated that the patent is a crucial step in protecting the company’s innovative treatments, highlighting its importance in advancing the CYB003 program. “The strength of our patents supporting CYB003 underscore our commitment to developing innovative, next-generation, commercially scalable therapeutics to address the significant unmet medical need in MDD,” Drysdale noted.

The announcement follows the recent Breakthrough Therapy Designation awarded to CYB003 by the U.S. Food and Drug Administration, marking another significant milestone in the regulatory pathway for this psychedelic-based treatment. With these advancements, Cybin is poised to accelerate the development and potential deployment of CYB003, aiming to provide a new therapeutic option for individuals suffering from MDD.